Fusing Artificial Intelligence and Machine Learning for Anti-Cancer Drug Discovery.

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
17 Oct 2024
Historique:
received: 14 10 2024
accepted: 17 10 2024
medline: 26 10 2024
pubmed: 26 10 2024
entrez: 26 10 2024
Statut: epublish

Résumé

The integration of artificial intelligence (AI) and machine learning (ML) in modern oncology is rapidly transforming cancer drug discovery and development [...].

Identifiants

DOI: 10.3390/cancers16203522 PMID: 39456615
pubmed: 39456615
pii: cancers16203522
doi: 10.3390/cancers16203522
pii:
doi:

Types de publication

Editorial

Langues

eng

Déclaration de conflit d'intérêts

The authors declare no conflicts of interest.

Auteurs

Christos Adamopoulos (C)

Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
ORCID: 0000-0001-6323-4216

Kostas A Papavassiliou (KA)

First University Department of Respiratory Medicine, 'Sotiria' Chest Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
ORCID: 0000-0001-9620-745X

Athanasios G Papavassiliou (AG)

Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
ORCID: 0000-0001-5803-4527

Classifications MeSH